Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve regeneration in vitro and in a mouse model

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Yagi, Hideki ^a   Ohkawara, Bisei ^a   Nakashima, Hiroaki ^a   Ito, Kenyu ^a   Tsushima, Mikito ^a   Ishii, Hisao ^a   Noto, Kimitoshi ^a   Ohta, Kyotaro ^a   Masuda, Akio ^a   Imagama, Shiro ^a   Ishiguro, Naoki ^a   Ohno, Kinji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN 4; STRESS ACTIVATED PROTEIN KINASE 1; TROPOMYOSIN RECEPTOR KINASE A; TROPOMYOSIN RECEPTOR KINASE B; UNCLASSIFIED DRUG; ZONISAMIDE; ISOXAZOLE DERIVATIVE; MESSENGER RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXON SIZE; BDNF GENE; CELL CULTURE; CELL DEATH; CELL ELONGATION; CELL SIZE; CELL VIABILITY; CHRNE GENE; COLQ GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION REGULATION; IN VITRO STUDY; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; NERVE REGENERATION; NEURITE; NEUROLOGIC DISEASE ASSESSMENT; NEUROPROTECTION; NGF GENE; NONHUMAN; NTF4 GENE; NTRK1 GENE; NTRK2 GENE; OXIDATIVE STRESS; RAPSN GENE; SCIATIC FUNCTION INDEX; SCIATIC NERVE INJURY; TIBIALIS ANTERIOR MUSCLE; TREATMENT DURATION; UPREGULATION; ANIMAL; AUTOGRAFT; C57BL MOUSE; CELL PROTECTION; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; SCIATIC NERVE; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; AUTOGRAFTS; CELL LINE, TUMOR; CELLS, CULTURED; CYTOPROTECTION; ISOXAZOLES; MALE; MICE, INBRED C57BL; MODELS, ANIMAL; MOTOR NEURONS; NERVE GROWTH FACTORS; NERVE REGENERATION; NEURITES; OXIDATIVE STRESS; RECEPTORS, NERVE GROWTH FACTOR; RNA, MESSENGER; SCIATIC NERVE; TIME FACTORS; UP-REGULATION;

EID: 84957111203     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142786     Document Type: Article

References (55)

1. Terenghi G. Peripheral nerve regeneration and neurotrophic factors. J Anat. 1999; 194 (Pt 1):1-14. Epub 1999/05/05. PMID: 10227662; PubMed Central PMCID: PMC1467889.
2. Namiki J, Kojima A, Tator CH. Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats. J Neurotrauma. 2000; 17(12):1219-31. Epub 2001/02/24. PMID: 11186234.
3. Coumans JV, Lin TT, Dai HN, MacArthur L, McAtee M, Nash C, et al. Axonal regeneration and functional recovery after complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins. J Neurosci. 2001; 21(23):9334-44. Epub 2001/11/22. PMID: 11717367.
4. Boyd JG, Gordon T. A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor. Eur J Neurosci. 2002; 15(4):613-26. Epub 2002/03/12. PMID: 11886442.
5. Tomaselli KJ, Reichardt LF. Peripheral motoneuron interactions with laminin and Schwann cell-derived neurite-promoting molecules: developmental regulation of laminin receptor function. J Neurosci Res. 1988; 21(2-4):275-85. Epub 1988/10/01. doi: 10.1002/jnr.490210220 PMID: 2975342.
6. Powell SK, Kleinman HK. Neuronal laminins and their cellular receptors. Int J Biochem Cell Biol. 1997; 29(3):401-14. Epub 1997/03/01. PMID: 9202420.
7. Brandenberger R, Kammerer RA, Engel J, Chiquet M. Native chick laminin-4 containing the beta 2 chain (s-laminin) promotes motor axon growth. J Cell Biol. 1996; 135(6 Pt 1):1583-92. doi: 10.1083/jcb. 135.6.1583 PMID: 8978824; PubMed Central PMCID: PMC2133966.
8. Marthiens V, Gavard J, Padilla F, Monnet C, Castellani V, Lambert M, et al. A novel function for cadherin-11 in the regulation of motor axon elongation and fasciculation. Mol Cell Neurosci. 2005; 28 (4):715-26. doi: 10.1016/j.mcn.2004.12.001 PMID: 15797718.
9. Pardridge WM, Kang YS, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res. 1994; 11(5):738-46. Epub 1994/05/01. PMID: 8058646.
10. Poduslo JF, Curran GL. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res Mol Brain Res. 1994; 23(1-2):157-62. Epub 1994/04/01. PMID: 8028478.
11. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996; 36(2):280-6. Epub 1996/03/01. PMID: 8965648.
12. Uemura T, Takamatsu K, Ikeda M, Okada M, Kazuki K, Ikada Y, et al. Transplantation of induced pluripotent stem cell-derived neurospheres for peripheral nerve repair. Biochem Biophys Res Commun. 2012; 419(1):130-5. doi: 10.1016/j.bbrc.2012.01.154 PMID: 22333572.
13. Nakamura M, Okano H. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res. 2013; 23(1):70-80. doi: 10.1038/cr.2012.171 PMID: 23229514; PubMed Central PMCID: PMC3541652.
14. Ramón-Cueto A, Cordero MI, Santos-Benito FF, Avila J. Functional Recovery of Paraplegic Rats and Motor Axon Regeneration in Their Spinal Cords by Olfactory Ensheathing Glia. Neuron. 2000; 25 (2):425-35. doi: 10.1016/s0896-6273(00)80905-8 PMID: 10719896
15. Wright KT, Uchida K, Bara JJ, Roberts S, El Masri W, Johnson WE. Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by coculture with bone marrow stromal cells. Spine J. 2014; 14 (8):1722-33. Epub 2014/01/28. doi: 10.1016/j.spinee.2014.01.021 PMID: 24462452.
16. Witheford M, Westendorf K, Roskams AJ. Olfactory ensheathing cells promote corticospinal axonal outgrowth by a L1 CAM-dependent mechanism. Glia. 2013; 61(11):1873-89. Epub 2013/09/17. doi: 10.1002/glia.22564 PMID: 24038549.
17. Spejo AB, Carvalho JL, Goes AM, Oliveira AL. Neuroprotective effects of mesenchymal stem cells on spinal motoneurons following ventral root axotomy: synapse stability and axonal regeneration. Neuroscience. 2013; 250:715-32. Epub 2013/07/31. doi: 10.1016/j.neuroscience.2013.07.043 PMID: 23896572.
18. Kurimoto S, Kato S, Nakano T, Yamamoto M, Takanobu N, Hirata H. Transplantation of embryonic motor neurons into peripheral nerve combined with functional electrical stimulation restores functional muscle activity in the rat sciatic nerve transection model. J Tissue Eng Regen Med. 2013. Epub 2014/03/29. doi: 10.1002/term.1844 PMID: 24668934.
19. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 2011; 59(4):763-75. Epub 2011/10/22. doi: 10.1111/j.1365-2559.2011.03993.x PMID: 22014056.
20. Fu Q, Hue J, Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci. 2007; 27(15):4154-64. Epub 2007/04/13. doi: 10.1523/JNEUROSCI.4353-06.2007 PMID: 17428993.
21. Cui SS, Yang CP, Bowen RC, Bai O, Li XM, Jiang W, et al. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res. 2003; 975(1-2):229-36. doi: 10.1016/s0006-8993(03)02699-4 PMID: 12763612.
22. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci. 2002; 22(15):6570-7. Epub 2002/08/02. doi: 20026637. PMID: 12151536.
23. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011; 57(2):153-60. doi: 10.4103/0022-3859.81870 PMID: 21654146.
24. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. doi: 10.1038/nrd1468 PMID: 15286734.
25. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992; 194(3):209-21. Epub 1992/07/01. doi: 10.1002/aja.1001940306 PMID: 1467557.
26. Jungnickel J, Haase K, Konitzer J, Timmer M, Grothe C. Faster nerve regeneration after sciatic nerve injury in mice over-expressing basic fibroblast growth factor. J Neurobiol. 2006; 66(9):940-8. doi: 10. 1002/neu.20265 PMID: 16758491.
27. Bain JR, Mackinnon SE, Hunter DA. Functional evaluation of complete sciatic, peroneal, and posterior tibial nerve lesions in the rat. Plast Reconstr Surg. 1989; 83(1):129-38. PMID: 2909054.
28. Jones G, Herczeg A, Ruegg MA, Lichtsteiner M, Kroger S, Brenner HR. Substrate-bound agrin induces expression of acetylcholine receptor epsilon-subunit gene in cultured mammalian muscle cells. Proc Natl Acad Sci U S A. 1996; 93(12):5985-90. PMID: 8650206; PubMed Central PMCID: PMCPMC39175.
29. Trinkaus M, Pregelj P, Trkov S, Sketelj J. Neural regulation of acetylcholinesterase-associated collagen Q in rat skeletal muscles. J Neurochem. 2008; 105(6):2535-44. doi: 10.1111/j.1471-4159.2008.05328. x PMID: 18373559.
30. Brockhausen J, Cole RN, Gervasio OL, Ngo ST, Noakes PG, Phillips WD. Neural agrin increases postsynaptic ACh receptor packing by elevating rapsyn protein at the mouse neuromuscular synapse. Dev Neurobiol. 2008; 68(9):1153-69. doi: 10.1002/dneu.20654 PMID: 18506821.
31. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004; 10(6):687-93. Epub 2004/02/18. PMID: 14965331.
32. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987; 413(1):185-8. Epub 1987/06/09. PMID: 2439177.
33. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996; 5(2):115-9. Epub 1996/06/01. PMID: 8795126.
34. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 1992; 12(1):21-7. Epub 1992/06/01. PMID: 1326433.
35. Yoshida S, Okada M, Zhu G, Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res. 2005; 67(3):153-62. Epub 2005/11/18. doi: 10.1016/j. eplepsyres.2005.10.001 PMID: 16289509.
36. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ. 1990; 39(1-4):13-7. Epub 1990/03/01. PMID: 1369646.
37. Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology. 2009; 57(3):322-31. Epub 2009/06/02. doi: 10.1016/j.neuropharm.2009.05.005 PMID: 19482038.
38. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol. 2010; 67(2):239-49. Epub 2010/03/13. doi: 10. 1002/ana.21885 PMID: 20225289.
39. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia. 1997; 38(9):975-80. Epub 1998/05/14. PMID: 9579935.
40. Komatsu M, Hiramatsu M, Willmore LJ. Zonisamide reduces the increase in 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia. 2000; 41 (9):1091-4. Epub 2000/09/22. PMID: 10999546.
41. Kawajiri S, Machida Y, Saiki S, Sato S, Hattori N. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett. 2010; 481(2):88-91. doi: 10.1016/j. neulet.2010.06.058 PMID: 20600601.
42. Choudhury ME, Sugimoto K, Kubo M, Iwaki H, Tsujii T, Kyaw WT, et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur J Pharmacol. 2012; 689(1-3):72-80. doi: 10.1016/j.ejphar.2012.05.012 PMID: 22659113.
43. Hirayama T, Yoshii Y, Kawabe K, Ikeda K. Zonisamide treatment delays motor neuron degeneration and astrocyte proliferation in wobbler mice. J Neurol Res. 2011; 1(4):139-44. doi: 10.4021/jnr59w
44. English AW, Liu K, Nicolini JM, Mulligan AM, Ye K. Small-molecule trkB agonists promote axon regeneration in cut peripheral nerves. Proc Natl Acad Sci U S A. 2013; 110(40):16217-22. doi: 10.1073/pnas.1303646110 PMID: 24043773; PubMed Central PMCID: PMC3791704.
45. Tsuda Y, Kanje M, Dahlin LB. Axonal outgrowth is associated with increased ERK 1/2 activation but decreased caspase 3 linked cell death in Schwann cells after immediate nerve repair in rats. BMC Neurosci. 2011; 12:12. Epub 2011/01/22. doi: 10.1186/1471-2202-12-12 PMID: 21251262; PubMed Central PMCID: PMCPmc3031266.
46. Wang Z, Wang J, Li J, Wang X, Yao Y, Zhang X, et al. MEK/ERKs signaling is essential for lithiuminduced neurite outgrowth in N2a cells. Int J Dev Neurosci. 2011; 29(4):415-22. Epub 2011/03/15. doi: 10.1016/j.ijdevneu.2011.03.001 PMID: 21397003.
47. Oliva AA Jr., Atkins CM, Copenagle L, Banker GA. Activated c-Jun N-terminal kinase is required for axon formation. J Neurosci. 2006; 26(37):9462-70. Epub 2006/09/15. doi: 10.1523/jneurosci.2625-06. 2006 PMID: 16971530.
48. Barnat M, Enslen H, Propst F, Davis RJ, Soares S, Nothias F. Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration. J Neurosci. 2010; 30 (23):7804-16. doi: 10.1523/JNEUROSCI.0372-10.2010 PMID: 20534829.
49. Guise S, Braguer D, Carles G, Delacourte A, Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res. 2001; 63(3):257-67. Epub 2001/02/15. PMID: 11170175.
50. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A. 1999; 96(22):12866-9. Epub 1999/10/27. PMID: 10536014; PubMed Central PMCID: PMC23136.
51. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001; 98(20):11569-74. Epub 2001/08/16. doi: 10.1073/pnas.181213498 PMID: 11504919; PubMed Central PMCID: PMCPmc58770.
52. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett. 2000; 288(2):163-6. Epub 2000/07/06. PMID: 10876086.
53. Barnes DG, Dourson M. Reference dose (RfD): description and use in health risk assessments. Regul Toxicol Pharmacol. 1988; 8(4):471-86. PMID: 3222488.
54. Dourson ML, Felter SP, Robinson D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul Toxicol Pharmacol. 1996; 24(2 Pt 1):108-20. doi: 10.1006/rtph.1996.0116 PMID: 8933624.
55. Foronda NM, Fowles J, Smith N, Taylor M, Temple W, Darlington C. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080). Regul Toxicol Pharmacol. 2007; 47(1):29-36. doi: 10.1016/j.yrtph.2006.08.005 PMID: 17030370.